Marijuana Reclassified

The Trump administration has reclassified state-licensed medical marijuana as a less dangerous drug, moving it from Schedule I to Schedule III. This change is expected to ease research barriers and potentially expand the use of medical marijuana. The move has been welcomed by cannabis companies, with shares rising in response to the news. The reclassification is seen as a major shift in US drug policy, with potential implications for the cannabis industry and medical research. The change is not expected to legalize the drug or make it available for recreational use, but rather to allow for more research and potential medical applications. The news has been covered by various outlets, with some focusing on the potential benefits for the cannabis industry and others highlighting the potential risks and uncertainties surrounding the change. Some outlets have also noted the potential implications for states where marijuana is already legal, and how the federal government's change in policy may affect these states.